Tessera Therapeutics
Anne-Virginie Eggimann joined Tessera in 2022 after leading the Regulatory Science function for nearly 11 years, most recently as Chief Regulatory Officer, at bluebird bio, Inc. As Tessera’s Chief Regulatory Officer, Anne-Virginie oversees several key functions responsible for driving forward the development of the company genome engineering products, including Regulatory Science, Program, Portfolio & Alliance Management, Program Leadership and Medical and Technical Writing. Ms. Eggimann is also responsible for Tessera’s Regulatory Intelligence & Policy activities.
Anne-Virginie has more than 20 years of experience in the development of innovative medicinal products, with a notable record of designing and executing robust regulatory strategies for bringing cell and gene therapies, oncology products and orphan drugs from early development to market.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.